Vaccines Europe pipeline review

Dashboard

Vaccines Europe conducted a pipeline review of its 14 member companies, including information up to August 2024.

The review shows a promising vaccines pipeline aimed at tackling the challenges of today and tomorrow, such as the burden of respiratory tract infections, AMR, the ageing of the population, climate change and zoonotic infections, through leveraging a broad array of technology platforms.

Overview data

98

vaccine candidates in Vaccines Europe membersโ€™ pipeline, of which 93 are prophylactic vaccines and 5 are therapeutic vaccines.

42%

of vaccine candidates aim to address disease areas for which no vaccine has been registered yet.

58%

of the vaccine candidates aim to further develop existing vaccines or find a new approach to address a disease.

30

of the vaccine candidates are for routine immunisation.

4

vaccine candidates aim to treat different types of cancer.

14%

of vaccine candidates are targeting antibiotic resistant pathogens.

Over 80%

of vaccine candidates are tested in adults and older adults.

12

different technology platforms are being used by Vaccines Europe members in their pipelines.

Over 65%

of vaccine candidates aim to tackle respiratory-transmitted diseases.

10%

of vaccine candidates are for travel.

30%

of vaccine candidates are focused on preventing zoonotic diseases.

5

vaccine candidates are for sexually-transmitted infections

Explore the latest vaccines in development

SEARCH BY

all_diseases_area
All Disease Areas
technology_platform
Technology Platforms
development_phases
Development Phases
trial_population
Trial Population

OR SEARCH BY REPORT SECTIONS

ico-antimicrobal
Antimicrobal resistance
ico-climate-change
Climate change
ico-infection-associated 60×60
Infection-associated cancer vaccines
ico-routine-vaccine
Routine vaccines across the lifespan
ico-therapeutic
Therapeutic vaccines
ico-travel-vaccines-1
Travel vaccines
ico-pandemic
Zoonoses and pandemic preparedness

Charts

By the end of August 2024, there were 98 vaccine candidates in the Vaccines Europe membersโ€™ pipeline. Most of these target infectious diseases caused by viruses. The majority of vaccine candidates target the adult population, especially for those at higher risk for serious disease infection. Meanwhile, almost half of the vaccine candidates target diseases for which there are no registered vaccines yet.

How can Europe take full advantage of this promising vaccines pipeline?

EU Vaccines Pipeline Review